Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Real-time Estimate Cboe BZX
Other stock markets
 01:35:57 2024-05-07 pm EDT 		5-day change 1st Jan Change
31.24 USD +2.71% Intraday chart for Supernus Pharmaceuticals, Inc. +3.92% +8.09%
05:48pm Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America MT
04:00pm M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 2023 Annual Report
PU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
GL
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
GL
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors
CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Supernus Provides Regulatory Update for SPN-830
GL
Supernus Provides Regulatory Update for SPN-830
AQ
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW